Abstract 363P
Background
Oral cancer is distressing cancer that affects physically and emotionally and is associated with an adverse impact on mental well-being and financial distress. Informal caregivers are a significant source of support to the patient during and after the treatment of cancer patients. Caregiving may become a burden leading to poor quality of life among caregivers. The study intends to evaluate the effect of a patient's financial distress and psychological well-being on the caregiver's health-related quality of life in early vs advanced oral cancer.
Methods
All oral cancer patients treated with curative intent at our institute from September 2019 to March 2022, with a minimum of 6 months follow-up and disease-free, were included in this study, along with the informal caregivers of the patients. Caretakers not suffering from chronically ill and incurable diseases are included in the study. Patients and caregivers were categorised into early-stage (Group A) and advanced-stage (Group B) based on the clinical staging of patients with oral cancer. The patient's financial distress was evaluated using the COST FACIT questionnaire, and Psychological well-being using DASS 21 questionnaire. The quality of life of the caregivers was evaluated using the WHOQOL BREF questionnaire.
Results
A total of 79 patients and their caregivers were included. The median age is 49 among patients and 38 among caregivers. Twenty-one were in Group A; the rest, fifty-eight, were in Group B. It was observed that the patient in group B has Significant financial distress (p<0.05). There was no difference in HRQOL among caregivers of both groups. There was no correlation between financial distress scores and the caregiver's QOL. There was no effect of the patient's psychological well-being on the QOL of caregivers in group A. However, patients with depression in group B had a significant impact on the caregivers' QOL in the psychological (p <0.05) and environmental domains (p <0.05).
Conclusions
The lack of psychological well-being of patients with advanced-stage cancer significantly influences informal caregivers' psychological and environmental quality of life domains.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
540P - Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
541P - Integrated analysis of randomized controlled trials IMpower130 and IMpower132 for advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Hibiki Udagawa
Session: Poster Display
Resources:
Abstract
542P - First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
Presenter: Zhen Wang
Session: Poster Display
Resources:
Abstract
543P - A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia
Presenter: Yuriko Ishida
Session: Poster Display
Resources:
Abstract
544P - Single cell level investigation of blood cells representing immune checkpoint inhibitor response in lung adenocarcinoma patients
Presenter: Juyong Seong
Session: Poster Display
Resources:
Abstract
545P - Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
Presenter: Andrew Fantoni
Session: Poster Display
Resources:
Abstract
546P - Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Presenter: Akio Tada
Session: Poster Display
Resources:
Abstract
547P - Immunotherapy outcome in advanced/metastatic lung cancer patients in real-world experience: Indian data
Presenter: Naveen K
Session: Poster Display
Resources:
Abstract
548P - B-Myb acts as a mentor instant promoter in non-small cell lung cancer by modifying the PD-1/PD-L1 axis
Presenter: Pan Xu
Session: Poster Display
Resources:
Abstract
549P - Drug-induced interstitial lung disease in patients with non-small cell lung cancer treated with immunotherapy for postoperative recurrence: Evaluation of CT findings and histopathological findings of the background lung
Presenter: shodai fujimoto
Session: Poster Display
Resources:
Abstract